MRKMerck Sharp & Dohme LLCRunning, no new patients
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Lung Cancer · Non-Small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 67 (final count)
- Started
- Nov 21, 2024
- Main results expected
- Mar 12, 2026
- Fully finished
- Apr 17, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose
Measured over: At designated time points (up to approximately 14 months)
Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State
Measured over: At designated time points (Up to ~15 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06698042 · record last updated 2026-07-21 · checked 2026-11-09 15:47 UTC